{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:27:48Z","timestamp":1787164068620,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020581","name":"AIRC Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 2024"],"award-info":[{"award-number":["IG 2024"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["30422"],"award-info":[{"award-number":["30422"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejca.2025.116155","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T16:02:02Z","timestamp":1764432122000},"page":"116155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Progression-free survival as a surrogate for overall survival in gastro-esophageal cancer trials with immunotherapy: A meta-analysis"],"prefix":"10.1016","volume":"232","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9365-2160","authenticated-orcid":false,"given":"Alberto Giovanni","family":"Leone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9639-4486","authenticated-orcid":false,"given":"Fausto","family":"Petrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4062-0808","authenticated-orcid":false,"given":"Samuel J.","family":"Klempner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghav","family":"Sundar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8591-9339","authenticated-orcid":false,"given":"Florian","family":"Lordick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Lorenzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micheal","family":"Masetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radka","family":"Obermannova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4835-7159","authenticated-orcid":false,"given":"Maria","family":"Alsina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5357-5858","authenticated-orcid":false,"given":"Yelena Y.","family":"Janjigian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8530-8420","authenticated-orcid":false,"given":"Filippo","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ejca.2025.116155_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103962","article-title":"Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups","volume":"9","author":"Leone","year":"2024","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.ejca.2025.116155_bib2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/jamaoncol.2022.5816","article-title":"Effectiveness of immune checkpoint inhibitors in patients with advanced esophageal squamous cell carcinoma: a meta-analysis including low PD-L1 subgroups","volume":"9","author":"Yap","year":"2023","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2025.116155_bib3","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/annonc\/mdv562","article-title":"Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents","volume":"27","author":"Saad","year":"2016","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.ejca.2025.116155_bib4","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/jnci\/djt269","article-title":"GASTRIC group. Progression-free survival as a surrogate for overall survival in advanced\/recurrent gastric cancer trials: a meta-analysis","volume":"105","author":"Paoletti","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2025.116155_bib5","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.ejca.2025.116155_bib6","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","article-title":"Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis","volume":"54","author":"Sterne","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ejca.2025.116155_bib7","unstructured":"Institute for Quality and Efficiency in Health Care: Executive Summaries [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2005\u2013. Validity of surrogate endpoints in oncology: Executive summary of rapid report A10-05, Version 1.1. 2011.."},{"issue":"1","key":"10.1016\/j.ejca.2025.116155_bib8","article-title":"Disease-free survival as a surrogate for overall survival in early-stage pancreatic cancer trials: a correlation meta-analysis","volume":"4","author":"Leite","year":"2025","journal-title":"BMJ Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2025.116155_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7235","article-title":"Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial","volume":"13","author":"Kato","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2025.116155_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-068714","article-title":"Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial","volume":"377","author":"Lu","year":"2022","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.ejca.2025.116155_bib11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ccell.2022.02.007","article-title":"Toripalimab plus chemotherapy in treatment-na\u00efve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial","volume":"40","author":"Wang","year":"2022","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.ejca.2025.116155_bib12","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial","volume":"326","author":"Luo","year":"2021","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ejca.2025.116155_bib13","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study","volume":"24","author":"Xu","year":"2023","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2025.116155_bib14","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41591-022-02179-2","article-title":"First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial","volume":"29","author":"Song","year":"2023","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.ejca.2025.116155_bib15","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41591-024-02797-y","article-title":"First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study","volume":"30","author":"Li","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2025.116155_bib16","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.3_suppl.245","article-title":"SKYSCRAPER-08: A phase III, randomized, double-blind, placebo-controlled study of first-line (1L) tiragolumab (tira) + atezolizumab (atezo) and chemotherapy (CT) in patients (pts) with esophageal squamous cell carcinoma (ESCC)","volume":"42","author":"Hsu","year":"2024","journal-title":"JCO"},{"issue":"10302","key":"10.1016\/j.ejca.2025.116155_bib17","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ejca.2025.116155_bib18","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2025.116155_bib19","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.4_suppl.243","article-title":"Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1\u2013positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial","volume":"40","author":"Wainberg","year":"2022","journal-title":"JCO"},{"issue":"17","key":"10.1016\/j.ejca.2025.116155_bib20","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1200\/JCO.23.01601","article-title":"First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III checkMate 649 trial","volume":"42","author":"Janjigian","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116155_bib21","article-title":"Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer\/gastroesophageal junction cancer\/esophageal adenocarcinoma (GC\/GEJC\/EAC): 5-year (y) follow-up results from CheckMate 649","volume":"43","author":"Jangijian","year":"2025","journal-title":"JCO"},{"issue":"7903","key":"10.1016\/j.ejca.2025.116155_bib22","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","article-title":"Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer","volume":"603","author":"Shitara","year":"2022","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ejca.2025.116155_bib23","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10418","key":"10.1016\/j.ejca.2025.116155_bib24","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"KEYNOTE-811 Investigators. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.ejca.2025.116155_bib25","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1001\/jama.2023.19918","article-title":"ORIENT-16 Investigators. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ejca.2025.116155_bib26","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.116155_bib27","article-title":"KEYNOTE-859: 4.5-year median follow-up of pembrolizumab plus chemotherapy for previously untreated advanced HER2-negative gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma","volume":"43","author":"Rha","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2025.116155_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"issue":"15","key":"10.1016\/j.ejca.2025.116155_bib29","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1001\/jama.2024.28463","article-title":"GEMSTONE-303 Investigators. First-LIne Sugemalimab plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 randomized clinical trial","volume":"333","author":"Zhang","year":"2025","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ejca.2025.116155_bib30","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/s41591-024-03450-4","article-title":"First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial","volume":"31","author":"Shen","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2025.116155_bib31","unstructured":"FDA Facts: Biomarkers and Surrogate Endpoints. Available at: \u3008https:\/\/www.fda.gov\/about-fda\/innovation-fda\/fda-facts-biomarkers-and-surrogate-endpoints\u3009. Accessed on 17\/06\/2025."},{"key":"10.1016\/j.ejca.2025.116155_bib32","unstructured":"Adaptive pathways. Available at: \u3008https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/adaptive-pathways#:~:text=confirming%20the%20benefit%2Drisk%20balance%20of%20a%20product%2C,endpoints)%20considered%20predictive%20of%20important%20clinical%20outcomes;&text=This%20concept%20applies%20primarily%20to%20treatments%20in,are%20unlikely%20to%20benefit%20from%20the%20medicine\u3009. Accessed on 17\/06\/2025."},{"issue":"7","key":"10.1016\/j.ejca.2025.116155_bib33","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1158\/1078-0432.CCR-22-2920","article-title":"Event-free survival as a surrogate for overall survival in gastric and gastroesophageal junction adenocarcinoma: a meta-analysis in the neoadjuvant \u00b1 adjuvant setting","volume":"29","author":"Wainberg","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2025.116155_bib34","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.21037\/atm.2018.09.31","article-title":"Surrogate study endpoints in the era of cancer immunotherapy","volume":"6","author":"Hamada","year":"2018","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ejca.2025.116155_bib35","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221131526","article-title":"Progression-free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma: a real-world data and literature-based analysis","volume":"14","author":"Han","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2025.116155_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcpo.2019.100202","article-title":"Is the number of cancer drug approvals a surrogate for regulatory success?","volume":"22","author":"Gyawali","year":"2019","journal-title":"J Cancer Policy"},{"issue":"2","key":"10.1016\/j.ejca.2025.116155_bib37","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/S1470-2045(24)00451-0","article-title":"Common sense oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials","volume":"26","author":"Gyawali","year":"2025","journal-title":"Lancet Oncol"},{"issue":"10389","key":"10.1016\/j.ejca.2025.116155_bib38","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ejca.2025.116155_bib39","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","author":"Shah","year":"2023","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.ejca.2025.116155_bib40","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s10147-009-0885-4","article-title":"Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials","volume":"14","author":"Shi","year":"2009","journal-title":"Int J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492501041X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492501041X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T23:11:48Z","timestamp":1773875508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492501041X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":40,"alternative-id":["S095980492501041X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116155","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progression-free survival as a surrogate for overall survival in gastro-esophageal cancer trials with immunotherapy: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116155","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116155"}}